Drug intelligence / Profile preview

ALY-202

Development stage: Preclinical
Lead developer: Alys Pharmaceuticals
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

ALY-202 is an investigational antibody-drug conjugate (ADC) being developed by Alys Pharmaceuticals for the treatment of systemic sclerosis (scleroderma). Originally part of the Granular Therapeutics pipeline before its integration into Alys, the drug is designed for subcutaneous administration. It utilizes a monoclonal antibody to deliver a therapeutic payload directly to specific cells involved in the pathogenesis of scleroderma, aiming to provide a targeted systemic treatment. As of early 2024, ALY-202 is in the IND-enabling phase of development, with an Investigational New Drug (IND) filing for a Phase 1/2 study anticipated in the second half of 2026.

Beyond the preview

Go deeper on ALY-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALY-202.

Explore the full profile